Decision Resources studied findings from the Pharmacor topic “Breast Cancer” that showed the possible financial effects of new therapies. Their findings projected a reduction in sales from generic and biosimilar erosion of some key agents in the next decade. However, they said this reduction will be offset by an annual increase in breast cancer incidence and the introduction of high-priced emerging therapies, according to the release.
Related Articles on Hospital Oncology:
CDC Releases Guide on Infection Prevention in Outpatient Oncology Settings
Brigham and Women’s, Dana-Farber Launch Research Project for Cancer Genomics
South Carolina’s St. Francis Health System Opens $3M Breast Health Center
